Researchers at Monash University and oNKo-Innate identified a gene whose inhibition in natural killer (NK) cells amplifies their sensitivity to IL-15, an immune growth factor imperative for cancer cell detection and killing. Preclinical colorectal cancer models showed enhanced tumor suppression upon boosting endogenous IL-15 signaling via this target. The gene encodes an enzyme amenable to small-molecule inhibition, proposing a safer alternative to direct IL-15 receptor agonists, with improved tumor-specific immune activation and reduced systemic toxicity.